Immunotherapy: Checkpoint Inhibitors in Lynch-Associated Gynecologic Cancers

  • J. Stuart FerrissEmail author
  • M. Yvette Williams-Brown
Gynecologic Cancers (LA Cantrell, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Gynecologic Cancers

Opinion statement

Research into novel therapies for gynecologic cancers is underfunded, and as a result, we are still playing catchup with other solid tumors in the realm of immune checkpoint inhibition. This is despite the fact that two of the most common gynecologic cancers in the USA have strong biologic rationales for response to these agents. Work is now underway to demonstrate safe and effective therapies for our patients. As we better understand the immune system, and more specifically the tumor microenvironment, we will be able to achieve complete responses. The immune system can learn, adapt, and provide ongoing surveillance; if only we could mimic its abilities.


Lynch syndrome Gynecologic cancers Immunotherapy Checkpoint inhibitors Endometrial cancer Ovarian cancer PD-1 PD-L1 


Compliance with Ethical Standards

Conflict of Interest

The authors declare they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Lynch HT, Lynch J. Lynch syndrome: genetics, natural history, genetic counseling, and prevention. J Clin Oncol. 2000;18(21 Suppl):19S–31S.PubMedGoogle Scholar
  2. 2.
    Lynch HT, Casey MJ, Lynch J, White TE, Godwin AK. Genetics and ovarian carcinoma. Semin Oncol. 1998;25(3):265–80.PubMedGoogle Scholar
  3. 3.
    Barrow E, Robinson L, Alduaij W, Shenton A, Clancy T, Lalloo F, et al. Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: a report of 121 families with proven mutations. Clin Genet. 2009;75(2):141–9.CrossRefGoogle Scholar
  4. 4.
    Schmeler KM, Soliman PT, Sun CC, Slomovitz BM, Gershenson DM, Lu KH. Endometrial cancer in young, normal-weight women. Gynecol Oncol. 2005;99(2):388–92.CrossRefGoogle Scholar
  5. 5.
    Dudley JC, Lin MT, Le DT, Eshleman JR. Microsatellite instability as a biomarker for PD-1 blockade. Clin Cancer Res. 2016;22(4):813–20.CrossRefGoogle Scholar
  6. 6.
    Boussiotis VA. Molecular and biochemical aspects of the PD-1 checkpoint pathway. N Engl J Med. 2016;375(18):1767–78.CrossRefGoogle Scholar
  7. 7.
    Iwai Y, Hamanishi J, Chamoto K, Honjo T. Cancer immunotherapies targeting the PD-1 signaling pathway. J Biomed Sci. 2017;24(1):26.CrossRefGoogle Scholar
  8. 8.
    Pietzner K, Nasser S, Alavi S, Darb-Esfahani S, Passler M, Muallem MZ, et al. Checkpoint-inhibition in ovarian cancer: rising star or just a dream? J Gynecol Oncol. 2018;29(6):e93.CrossRefGoogle Scholar
  9. 9.
    Hamanishi J, Mandai M, Matsumura N, Abiko K, Baba T, Konishi I. PD-1/PD-L1 blockade in cancer treatment: perspectives and issues. Int J Clin Oncol. 2016;21(3):462–73.CrossRefGoogle Scholar
  10. 10.
    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34.CrossRefGoogle Scholar
  11. 11.
    Cronin KA, Lake AJ, Scott S, Sherman RL, Noone AM, Howlader N, et al. Annual report to the nation on the status of cancer, part I: national cancer statistics. Cancer. 2018;124(13):2785–800.CrossRefGoogle Scholar
  12. 12.
    McMeekin DS, Filiaci VL, Thigpen JT, Gallion HH, Fleming GF, Rodgers WH, et al. The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a gynecologic oncology group study. Gynecol Oncol. 2007;106(1):16–22.CrossRefGoogle Scholar
  13. 13.
    Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983;15(1):10–7.CrossRefGoogle Scholar
  14. 14.
    • Cancer Genome Atlas Research N, Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497(7447):67–73 Landmark paper that shifted our understanding of how to classify endometrial cancers.CrossRefGoogle Scholar
  15. 15.
    Zou W, Wolchok JD, Chen L. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations. Sci Transl Med. 2016;8(328):328rv4.CrossRefGoogle Scholar
  16. 16.
    • Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509–20 Demonstrated the potential of checkpoint inhibitors in dMMR tumors, including gynecologic cancers.CrossRefGoogle Scholar
  17. 17.
    Herzog TJ, Arguello D, Reddy SK, Gatalica Z. PD-1, PD-L1 expression in 1599 gynecological cancers: implications for immunotherapy. Gynecol Oncol. 2015;137:204–5.CrossRefGoogle Scholar
  18. 18.
    Eggink FA, Van Gool IC, Leary A, Pollock PM, Crosbie EJ, Mileshkin L, et al. Immunological profiling of molecularly classified high-risk endometrial cancers identifies POLE-mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition. Oncoimmunology. 2017;6(2):e1264565.CrossRefGoogle Scholar
  19. 19.
    Ott PA, Bang YJ, Berton-Rigaud D, Elez E, Pishvaian MJ, Rugo HS, et al. Safety and antitumor activity of pembrolizumab in advanced programmed death ligand 1-positive endometrial cancer: results from the KEYNOTE-028 study. J Clin Oncol. 2017;35(22):2535–41.CrossRefGoogle Scholar
  20. 20.
    •• Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357(6349):409–13 Established checkpoint inhibitors as a therapeutic option for dMMR tumors, regardless of tissue of origin.CrossRefGoogle Scholar
  21. 21.
    Lemery S, Keegan P, Pazdur R. First FDA approval agnostic of Cancer site - when a biomarker defines the indication. N Engl J Med. 2017;377(15):1409–12.CrossRefGoogle Scholar
  22. 22.
    Santin AD, Bellone S, Buza N, Choi J, Schwartz PE, Schlessinger J, et al. Regression of chemotherapy-resistant polymerase epsilon (POLE) ultra-mutated and MSH6 hyper-mutated endometrial tumors with nivolumab. Clin Cancer Res. 2016;22(23):5682–7.CrossRefGoogle Scholar
  23. 23.
    Fuh K, Lomonosova E, Guo L, Fantl W, Pachynski R, Malkova O, et al. Identifying a potential biomarker for anti-PD-1 immunotherapy in patients with advanced stage, surgically-resectable endometrial cancer. ASCO Annual Meeting; June 1, 2019; Chicago, IL. J Clin Oncol. 2019;37(suppl; abstr 5590).CrossRefGoogle Scholar
  24. 24.
    Secord AA. A study of pembrolizumab on the tumoral immunoprofile of gynecologic cancers. NCT02728830. NCI; [Available from: Accessed 14 June 2019.
  25. 25.
    Santin AD. Pembrolizumab in ultramutated and hypermutated endometrial cancer. NCT02899793. NCI; [Available from: Accessed 14 June 2019.
  26. 26.
    Makker V, Rasco D, Vogelzang NJ, Brose MS, Cohn AL, Mier J, et al. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2019;20(5):711–8.CrossRefGoogle Scholar
  27. 27.
    Makker V, Herraez A, Aghajanian C, Fujiwara K, Pignata S, Penson RT, et al. A phase 3 trial evaluating efficacy and safety of lenvatinib in combination with pembrolizumab in patients with advanced endometrial cancer. ASCO Annual Meeting; June 1, 2019; Chicago, IL. J Clin Oncol. 2019;37(suppl; abstr TPS5607).CrossRefGoogle Scholar
  28. 28.
    Eskander RN, NRG-Oncology. Testing the addition of the immunotherapy drug pembrolizumab to the usual chemotherapy treatment (paclitaxel and carboplatin) in stage iii-iv or recurrent endometrial cancer, NCT03914612. NCI; [Available from: Accessed 14 June 2019.
  29. 29.
    Willis BC, Sloan EA, Atkins KA, Stoler MH, Mills AM. Mismatch repair status and PD-L1 expression in clear cell carcinomas of the ovary and endometrium. Mod Pathol. 2017;30(11):1622–32.CrossRefGoogle Scholar
  30. 30.
    Al-Hussaini M, Lataifeh I, Jaradat I, Abdeen G, Otay L, Badran O, et al. Undifferentiated endometrial carcinoma, an immunohistochemical study including PD-L1 testing of a series of cases from a single cancer center. Int J Gynecol Pathol. 2018;37(6):564–74.CrossRefGoogle Scholar
  31. 31.
    Antill Y, Kok P, Robledo K, Barnes E, Friedlander M, Baron-Hay S, et al. Activity of durvalumab in advanced endometrial cancer (AEC) according to mismatch repair (MMR) status: The phase II PHAEDRA trial (ANZGOG1601). ASCO Annual Meeting; June 3, 2019; Chicago, IL. J Clin Oncol. 2019;37(suppl; abstr 5501).CrossRefGoogle Scholar
  32. 32.
    Konstantinopoulos PA, Liu JF, Luo W, Krasner CN, Ishizuka J, Gockley A, et al. Phase 2, two-group, two-stage study of avelumab in patients (pts) with microsatellite stable (MSS), microsatellite instable (MSI), and polymerase epsilon (POLE) mutated recurrent/persistent endometrial cancer (EC). ASCO Annual Meeting; June 3, 2019; Chicago, IL. J Clin Oncol. 2019;37(suppl;abstr 5502).Google Scholar
  33. 33.
    Colombo N, Barretina-Ginesta M, Beale P, Harano K, Hudson E, Marme F, et al. AtEnd/ENGOT-en7: A multicenter phase III double-blind randomized controlled trial of atezolizumab in combination with paclitaxel and carboplatin in women with advanced/recurrent endometrial cancer. . ASCO Annual Meeting; June 1, 2019; Chicago, IL. J Clin Oncol. 2019;37(suppl; abst TPS5608).Google Scholar
  34. 34.
    Rubinstein M, Caird I, Zhou Q, Iasonos A, Friedman C, Cadoo K, et al. A phase II trial of durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial carcinoma and endometrial carcinosarcoma. . ASCO Annual Meeting June 1, 2019; Chicago, IL J Clin Oncol. 2019;37(suppl; abstr 5582).CrossRefGoogle Scholar
  35. 35.
    Oh MS, Chae YK. Deep and durable response with combination CTLA-4 and PD-1 blockade in mismatch repair (MMR)-proficient endometrial cancer. J Immunother. 2019;42(2):51–4.CrossRefGoogle Scholar
  36. 36.
    Antomarchi J, Ambrosetti D, Cohen C, Delotte J, Chevallier A, Karimdjee-Soilihi B, Ngo-Mai M, Schmid-Alliana A, Schmid-Antomarchi H. Immunosuppressive tumor microenvironment status and histological grading of endometrial carcinoma. Cancer Microenviron. 2019.Google Scholar
  37. 37.
    Winer I, Jones NL, Xiu J, Ellerbrock A, Brown J, Herzog T. Mutational burden, tumor immune checkpoint expression, and microsatellite instability in gynecologic malignancies: implications for immune therapy. Gynecol Oncol. 2018;149:45.CrossRefGoogle Scholar
  38. 38.
    Jones NL, Xiu J, Herzog T, Winer I. Immune checkpoint expression, microsatellite instability, and mutational burden: identifying immune biomarker phenotypes in uterine cancer. Gynecol Oncol. 2018;149:44.CrossRefGoogle Scholar
  39. 39.
    Yamashita H, Nakayama K, Ishikawa M, Nakamura K, Ishibashi T, Sanuki K, et al. Microsatellite instability is a biomarker for immune checkpoint inhibitors in endometrial cancer. Oncotarget. 2018;9(5):5652–64.CrossRefGoogle Scholar
  40. 40.
    Moore M, Ring KL, Mills AM. TIM-3 in endometrial carcinomas: an immunotherapeutic target expressed by mismatch repair-deficient and intact cancers. Mod Pathol. 2019;32:1168–79.CrossRefGoogle Scholar
  41. 41.
    Asaka S, Yen TT, Wang TL, Shih IM, Gaillard S. T cell-inflamed phenotype and increased Foxp3 expression in infiltrating T-cells of mismatch-repair deficient endometrial cancers. Mod Pathol. 2019;32(4):576–84.CrossRefGoogle Scholar
  42. 42.
    Wortman BG, Bosse T, Nout RA, Lutgens LCHW, van der Steen-Banasik EM, Westerveld H, et al. Molecular-integrated risk profile to determine adjuvant radiotherapy in endometrial cancer: evaluation of the pilot phase of the PORTEC-4a trial. Gynecol Oncol. 2018;151(1):69–75.CrossRefGoogle Scholar
  43. 43.
    Lee L, Matulonis U. Immunotherapy and radiation combinatorial trials in gynecologic cancer: a potential synergy? Gynecol Oncol. 2019.Google Scholar
  44. 44.
    Son CH, Fleming GF, Moroney JW. Potential role of radiation therapy in augmenting the activity of immunotherapy for gynecologic cancers. Cancer Manag Res. 2017;9:553–63.CrossRefGoogle Scholar
  45. 45.
    Reijnen C, Küsters-Vandevelde HVN, Prinsen CF, Massuger LFAG, Snijders MPML, Kommoss S, et al. Mismatch repair deficiency as a predictive marker for response to adjuvant radiotherapy in endometrial cancer. Gynecol Oncol. 2019.Google Scholar
  46. 46.
    Talhouk A, McConechy MK, Leung S, Yang W, Lum A, Senz J, et al. Confirmation of ProMisE: a simple, genomics-based clinical classifier for endometrial cancer. Cancer. 2017;123(5):802–13.CrossRefGoogle Scholar
  47. 47.
    Britton H, Huang L, Lum A, Leung S, Shum K, Kale M, et al. Molecular classification defines outcomes and opportunities in young women with endometrial carcinoma. Gynecol Oncol. 2019;153(3):487–95.CrossRefGoogle Scholar
  48. 48.
    •• Talhouk A, Derocher H, Schmidt P, Leung S, Milne K, Gilks CB, et al. Molecular subtype not immune response drives outcomes in endometrial carcinoma. Clin Cancer Res. 2019;25(8):2537–48 A remarkable paper that further demonstrated the utility of the ProMisE classification of endometrial cancers, as well as the significance of TILs in the microenvironment.CrossRefGoogle Scholar
  49. 49.
    Mullen MM, Mutch DG. Endometrial tumor immune response: predictive biomarker of response to immunotherapy. Clin Cancer Res. 2019;25(8):2366–8.CrossRefGoogle Scholar
  50. 50.
    Bookman MA, Brady MF, McGuire WP, Harper PG, Alberts DS, Friedlander M, et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the gynecologic cancer InterGroup. J Clin Oncol. 2009;27:1419–25.CrossRefGoogle Scholar
  51. 51.
    • Hamanishi J, Mandai M, Ikeda T, Minami M, Kawaguchi A, Murayama T, et al. Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer. J Clin Oncol. 2015;33(34):4015–22 Demonstrated the use of checkpoint inhibitors in ovarian cancer.CrossRefGoogle Scholar
  52. 52.
    Hamanishi J, Murakami R, Baba T, Yamaguchi K, Abiko K, Mandai M. Passenger fusion genes are correlated to antitumor effect of anti-PD-1 antibody nivolumab for ovarian cancer. 2019 SGO annual meeting; march 2019; Honolulu, HI.Google Scholar
  53. 53.
    Varga A, Piha-Paul S, Ott PA, Mehnert JM, Berton-Rigaud D, Morosky A, et al. Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: analysis of KEYNOTE-028. Gynecol Oncol. 2019;152(2):243–50.CrossRefGoogle Scholar
  54. 54.
    Bellone S, Buza N, Choi J, Zammataro L, Gay L, Elvin J, et al. Exceptional response to pembrolizumab in a metastatic, chemotherapy/radiation-resistant ovarian cancer patient harboring a PD-L1-genetic rearrangement. Clin Cancer Res. 2018;24(14):3282–91.CrossRefGoogle Scholar
  55. 55.
    Disis ML, Taylor MH, Kelly K, Beck JT, Gordon M, Moore KM, et al. Efficacy and safety of avelumab for patients with recurrent or refractory ovarian cancer: phase 1b results from the JAVELIN solid tumor trial. JAMA Oncol. 2019;5:393–401.CrossRefGoogle Scholar
  56. 56.
    Emens LA, Kok M, Ojalvo LS. Targeting the programmed cell death-1 pathway in breast and ovarian cancer. Curr Opin Obstet Gynecol. 2016;28(2):142–7.CrossRefGoogle Scholar
  57. 57.
    Zhang G, Liu C, Bai H, Cao G, Cui R, Zhang Z. Combinatorial therapy of immune checkpoint and cancer pathways provides a novel perspective on ovarian cancer treatment. Oncol Lett. 2019;17(3):2583–91.PubMedPubMedCentralGoogle Scholar
  58. 58.
    Pujade-Lauraine E, Fujiwarab K, Ledermann JA, Oza A, Kristeleit R, Ray-Coquard I, et al. Avelumab alone or in combination with pegylated liposomal doxorubicin versus pegylated liposomal doxorubicin alone in platinum-resistant or refractory epithelial ovarian cancer: primary and biomarker analysis of the phase III JAVELIN Ovarian 200 trial. 2019 SGO Annumal meeting; march 17, 2019; Honolulu, HI.Google Scholar
  59. 59.
    Liao JB, Gwin W, Urban R, Hitchcock-Bernhardt K, Coveler A, Higgins D, et al. Pembrolizumab with low dose carboplatin for recurrent platinum resistant ovarian, fallopian tube, and primary peritoneal cancer-interim results. 2019 ASCO annual meeting; Chicago, IL. J Clin Oncol. 2019;37(suppl; abstr 5519).CrossRefGoogle Scholar
  60. 60.
    Moore KN, Pignata S. Trials in progress: IMagyn050/GOG 3015/ENGOT-OV39. A phase III, multicenter, randomized study of atezolizumab versus placebo administered in combination with paclitaxel, carboplatin, and bevacizumab to patients with newly-diagnosed stage III or stage IV ovarian, fallopian tube, or primary peritoneal cancer. Int J Gynecol Cancer. 2019.Google Scholar
  61. 61.
    Liu YL, Zamarin D. Combination immune checkpoint blockade strategies to maximize immune response in gynecological cancers. Curr Oncol Rep. 2018;20(12):94.CrossRefGoogle Scholar
  62. 62.
    Penn C, Lester J, Bohrer K, Moon C, Yearley J, Karlan BY, et al. PD-1/PD-L1 expression in BRCA1/2 mutated ovarian cancers. 2019 SGO annual meeting march 2019; Honolulu, HI.Google Scholar
  63. 63.
    Konstantinopoulos PA, Waggoner S, Vidal GA, Mita M, Moroney JW, Holloway R, et al. Single-arm phases 1 and 2 trial of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma. JAMA Oncol. 2019;5:1141.CrossRefGoogle Scholar
  64. 64.
    Monk BJ, Coleman RL, Fujiwara K, Oza AM, Westin SN, O’Malley DM, et al. ATHENA (GOG-3020/ENGOT-ov45): a randomised, double-blind, placebo-controlled, phase 3 study of rucaparib + nivolumab following front-line platinum-based chemotherapy in ovarian cancer. 2018 International Gynecologic Cancer Society Biennial Meeting; Kyoto, Japan.Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Gynecology and ObstetricsJohns Hopkins University School of MedicineBaltimoreUSA
  2. 2.Departments of Women’s Health and OncologyThe University of Texas at Austin Dell Medical SchoolAustinUSA

Personalised recommendations